- Teladoc shareholders had a rough couple of months as shares declined by more than 40% YTD and are down roughly 60% from all-time highs in February.
- Telehealth has seen rapid uptake during the pandemic and utilization rates continue to be more than 30-times higher than pre-pandemic.
- McKinsey estimated that telehealth could become a >$250bn annual market opportunity in the US alone.
- Teladoc has pioneered the telehealth industry and has shown strong operating performance while many competitors are failing to keep up.
- The big question is if the stock can shake off the negative sentiment as a Covid stock and reverse its downtrend. We believe it can.
For further details see:
Teladoc: Understanding The Difference Between A Broken Company And A Broken Stock